Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS

References

• Brown RH, Jr., Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:1602.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications. Front Immunol. 2017;8:1005.
   PubMed Web of Science ®Google Scholar
• Ndayisaba A, Kaindlstorfer C, Wenning GK. Iron in neurodegeneration – cause or consequence? Front Neurosci. 2019;13:180.
   PubMed Web of Science ®Google Scholar
• Donnelly CJ, Grima JC, Sattler R. Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets? Neurodegener Dis Manag. 2014;4:417–37.
   PubMedGoogle Scholar
• Shan G, Li Y, Zhang J, Li W, Szulwach KE, Duan R, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol. 2008;26:933–40.
   PubMed Web of Science ®Google Scholar
• Ricci C, Marzocchi C, Battistini S. MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells. 2018;7:219.
   PubMed Web of Science ®Google Scholar
• Badal S, Her YF, Maher LJ. 3rd. Nonantibiotic effects of fluoroquinolones in mammalian cells. J Biol Chem. 2015;290:22287–97.
   PubMed Web of Science ®Google Scholar
• Nunez MT, Chana-Cuevas P. New perspectives in iron chelation therapy for the treatment of neurodegenerative diseases. Pharmaceuticals (Basel). 2018;11:109.
   PubMedGoogle Scholar
• Knopfová L, Smarda J. The use of Cox-2 and PPARγ signaling in anti-cancer therapies. Exp Ther Med. 2010;1:257–64.
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
   PubMed Web of Science ®Google Scholar
• Goldshtein H, Muhire A, Petel Legare V, Pushett A, Rotkopf R, Shefner JM, et al. Efficacy of ciprofloxacin/celecoxib combination in zebrafish models of amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1883–97.
   PubMed Web of Science ®Google Scholar
• Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front Neurol. 2018;9:1167.
   PubMed Web of Science ®Google Scholar
• Chen PC, Wu D, Hu CJ, Chen HY, Hsieh YC, Huang CC. Exosomal TAR DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: a longitudinal follow-up study. J Neurol Sci. 2020;418:117070.
   PubMed Web of Science ®Google Scholar
• Menzies FM, Fleming A, Caricasole A, Bento CF, Andrews SP, Ashkenazi A, et al. Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. Neuron 2017;93:1015–34.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
   PubMed Web of Science ®Google Scholar
• Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.
   PubMed Web of Science ®Google Scholar
• Thery C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7:1535750.
   PubMed Web of Science ®Google Scholar
• Delgado-Peraza F, Nogueras-Ortiz CJ, Volpert O, Liu D, Goetzl EJ, Mattson MP, et al. Neuronal and astrocytic extracellular vesicle biomarkers in blood reflect brain pathology in mouse models of Alzheimer’s disease. Cells 2021;10:993.
   PubMed Web of Science ®Google Scholar
• Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423–33.
   PubMed Web of Science ®Google Scholar
• Beaulieu D, Berry JD, Paganoni S, Glass JD, Fournier C, Cuerdo J, et al. Development and validation of a machine-learning ALS survival model lacking vital capacity (VC-Free) for use in clinical trials during the COVID-19 pandemic. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:22–32.
   PubMed Web of Science ®Google Scholar
• Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2018;5:1522–33.
   PubMed Web of Science ®Google Scholar
• Smith RA, Kaspar B, Svendsen C. Neurotherapeutics in the era of translational medicine. 1st ed. San Diego: Academic Press, Elsevier: Amsterdam; 2020.
   Google Scholar
• Gold J, Rowe DB, Kiernan MC, Vucic S, Mathers S, van Eijk RPA, et al. Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:595–604.
   PubMed Web of Science ®Google Scholar
• Berry JD, Taylor AA, Beaulieu D, Meng L, Bian A, Andrews J, et al. Improved stratification of ALS clinical trials using predicted survival. Ann Clin Transl Neurol. 2018;5:474–85.
   PubMed Web of Science ®Google Scholar
• Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719–25.
   PubMed Web of Science ®Google Scholar
• Pinheiro J, Bornkamp B, Glimm E, Bretz F. Model-based dose finding under model uncertainty using general parametric models. Stat Med. 2014;33:1646–61.
   PubMed Web of Science ®Google Scholar
• Zach N, Ennist DL, Taylor AA, Alon H, Sherman A, Kueffner R, et al. Being PRO-ACTive: what can a clinical trial database reveal about ALS? Neurotherapeutics. 2015;12:417–23.
   PubMed Web of Science ®Google Scholar
• Kuffner R, Zach N, Norel R, Hawe J, Schoenfeld D, Wang L, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol. 2015;33:51–7.
   PubMed Web of Science ®Google Scholar
• Madill M, McDonagh K, Ma J, Vajda A, McLoughlin P, O'Brien T, et al. Amyotrophic lateral sclerosis patient iPSC-derived astrocytes impair autophagy via non-cell autonomous mechanisms. Mol Brain. 2017;10:22.
   PubMed Web of Science ®Google Scholar
• Goutman SA, Brown MB, Glass JD, Boulis NM, Johe K, Hazel T, et al. Long-term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Ann Clin Transl Neurol. 2018;5:730–40.
   PubMed Web of Science ®Google Scholar
• Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science 2020;367. DOI:10.1126/science.aau6977
   PubMed Web of Science ®Google Scholar
• Hornung S, Dutta S, Bitan G. CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges. Front Mol Neurosci. 2020;13:38.
   PubMed Web of Science ®Google Scholar
• Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668–72.
   PubMed Web of Science ®Google Scholar
• Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18:90.
   PubMed Web of Science ®Google Scholar
• Iguchi Y, Eid L, Parent M, Soucy G, Bareil C, Riku Y, et al. Exosome secretion is a key pathway for clearance of pathological TDP-43. Brain. 2016;139:3187–201.
   PubMed Web of Science ®Google Scholar
• Huang S, Sinicrope FA. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy 2010;6:256–69.
   PubMed Web of Science ®Google Scholar
• Oberstadt M, Claßen J, Arendt T, Holzer M. TDP-43 and cytoskeletal proteins in ALS. Mol Neurobiol. 2018;55:3143–51.
   PubMed Web of Science ®Google Scholar
• Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103–16.
   PubMed Web of Science ®Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
   PubMed Web of Science ®Google Scholar